$0.37
0[0.00%]
At close: Apr 18
Agile Therapeutics
(OTCPK:AGRX)Agile Therapeutics Stock (OTC:AGRX), Analyst Ratings, Price Targets, Predictions
Agile Therapeutics Inc has a consensus price target of $4.25, established from looking at the 11 latest analyst ratings. The last 3 analyst ratings were released from Maxim Group, Maxim Group, and HC Wainwright & Co. on March 18, 2024, September 22, 2023, and June 26, 2023. With an average price target of $5.67 between Maxim Group, Maxim Group, and HC Wainwright & Co., there's an implied 1431.53% upside for Agile Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Maxim Group
HC Wainwright & Co.
Maxim Group
RBC Capital
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Agile Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/18/2024 | AGRX | Buy Now | Agile Therapeutics | $0.37 | — | Maxim Group | Naz Rahman | — | Downgrade | Buy → Hold | Get Alert |
| 09/22/2023 | AGRX | Buy Now | Agile Therapeutics | $0.37 | 1251.35% | Maxim Group | Naz Rahman | → $5 | Upgrade | Hold → Buy | Get Alert |
| 06/26/2023 | AGRX | Buy Now | Agile Therapeutics | $0.37 | 3143.24% | HC Wainwright & Co. | Oren Livnat | → $12 | Reiterates | Buy → Buy | Get Alert |
| 06/07/2023 | AGRX | Buy Now | Agile Therapeutics | $0.37 | 3143.24% | HC Wainwright & Co. | Oren Livnat | → $12 | Reiterates | Buy → Buy | Get Alert |
| 12/30/2022 | AGRX | Buy Now | Agile Therapeutics | $0.37 | 710.81% | HC Wainwright & Co. | Oren Livnat | $250 → $150 | Maintains | Buy | Get Alert |
| 07/26/2022 | AGRX | Buy Now | Agile Therapeutics | $0.37 | 170.27% | Maxim Group | Naz Rahman | → $50 | Upgrade | Hold → Buy | Get Alert |
| 07/11/2022 | AGRX | Buy Now | Agile Therapeutics | $0.37 | 1251.35% | HC Wainwright & Co. | Oren Livnat | $125 → $250 | Maintains | Buy | Get Alert |
| 04/08/2022 | AGRX | Buy Now | Agile Therapeutics | $0.37 | — | Maxim Group | Caroline Palomeque | — | Downgrade | Buy → Hold | Get Alert |
| 11/03/2021 | AGRX | Buy Now | Agile Therapeutics | $0.37 | 575.68% | HC Wainwright & Co. | Oren Livnat | — | Maintains | Buy | Get Alert |
| 09/13/2021 | AGRX | Buy Now | Agile Therapeutics | $0.37 | 845.95% | HC Wainwright & Co. | Oren Livnat | — | Maintains | Buy | Get Alert |
| 07/27/2021 | AGRX | Buy Now | Agile Therapeutics | $0.37 | 1251.35% | RBC Capital | Daniel Busby | — | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Agile Therapeutics (AGRX)?
The latest price target for Agile Therapeutics (OTCPK: AGRX) was reported by Maxim Group on March 18, 2024. The analyst firm set a price target for $0.00 expecting AGRX to fall to within 12 months (a possible -100.00% downside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Agile Therapeutics (AGRX)?
The latest analyst rating for Agile Therapeutics (OTCPK: AGRX) was provided by Maxim Group, and Agile Therapeutics downgraded their hold rating.
When was the last upgrade for Agile Therapeutics (AGRX)?
The last upgrade for Agile Therapeutics Inc happened on September 22, 2023 when Maxim Group raised their price target to $5. Maxim Group previously had a hold for Agile Therapeutics Inc.
When was the last downgrade for Agile Therapeutics (AGRX)?
The last downgrade for Agile Therapeutics Inc happened on March 18, 2024 when Maxim Group changed their price target from N/A to N/A for Agile Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Agile Therapeutics (AGRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Agile Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Agile Therapeutics was filed on March 18, 2024 so you should expect the next rating to be made available sometime around March 18, 2025.
Is the Analyst Rating Agile Therapeutics (AGRX) correct?
While ratings are subjective and will change, the latest Agile Therapeutics (AGRX) rating was a downgraded with a price target of $0.00 to $0.00. The current price Agile Therapeutics (AGRX) is trading at is $0.37, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.